ReviewThe AAPS journal2026
Nanotechnology-enhanced Natural Products for Cancer Chemoprevention: Molecular Mechanisms and Clinical Translation.
Review in The AAPS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a major global health challenge. Natural compounds, such as curcumin, resveratrol, genistein, thymoquinone, and paclitaxel, show chemopreventive activity by modulating signaling pathways, including PI3K/Akt, NF-κB, and p53. These agents also promote apoptosis, autophagy, and DNA repair. However, their clinical use is restricted by poor solubility, instability, and low bioavailability. Nanotechnology offers solutions by improving stability, enhancing pharmacokinetics, and enabling targeted delivery. Liposomes, polymeric nanoparticles, dendrimers, and albumin-bound systems amplify the anticancer effects of natural compounds. Preclinical studies confirm improved efficacy, while early clinical trials reveal both promise and barriers. The key translational challenges include immune clearance, large-scale reproducibility, and regulatory approval. This review highlights the synergy between nanotechnology and natural compounds in cancer chemoprevention and outlines opportunities for future research.
Indexed as
Identifiers
42128977What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.